Cell and gene therapies are taking off in a big way in Europe. As the buzz grows, the Swedish firm Ilya Pharma has raised €8.5M to lay down the foundations of bacterial gene therapies for enterocolitis and diabetic ulcers.
Nordic Life Science shares our news about planning for clinical developments for ILP100-Oral, being developed for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors
Therapeutic concepts, work and science being recognised for significant contributions in the advanced therapy pipeline in the MedicineMakers PowerList 2021.
Clinical team publishes peer-reviewed expert opinion on how to optimise development of topical medicines, especially cell- and gene therapies
The team also published an expert opinion on the mechanism of actions explored and progress of pipeline in 2019 in Öhnstedt et al., Expert Opinion on Drug Discovery 2019;14(5):485-497.
First Word Pharma shares the news that Ilya Pharma was especially selected to Present ILP100 Accelerated Wound Healing Gene Therapy at US Military Health System Research Symposium (MHSRS) 2021
New podcast with the co-founders of Ilya Pharma - moving quickly and efficiently forward and building a top notch team
Science of the MOA and benefits of CXCL12 to accelerate healing highlighted in Nature Cardiology Reviews
The scientific findings of macrophages regulating blood flow in injured tissue and how CXCL12 is therapeutically facilitating this mechanism of action accelerating healing is highlighted by Nature Cardiology Reviews. Original article: Vågesjö, E. et al. Perivascular macrophages regulate blood flow following tissue damage. Circ. Res. https://doi.org/10.1161/CIRCRESAHA.120.318380 (2021)
Blood flow regulating Macrophages, the science behind the scalable iLP-technology platform and lead candidate ILP100 published in Circulation Research
Evelina Vågesjö CEO of Ilya Pharma included in the 2021 Power List in Advanced therapies by the Medicine Maker
Our CEO Evelina Vågesjö is listed for Advanced therapies by the TheMedicineMaker together with the former Head och Cell- and Genetherapies at Novartis bringing the first CAR T cell therapy to market and the recent Nobel Laureates and users of the CRISPER technology. The ILP-drug candidates and the lead candidate ILP100 developed in Topical and Oral formulations is indeed advanced therapy, it is a next generation immunotherapy and are developed to treat wounds in skin and mucosa.